ES3005508T3 - Compositions and methods for beta secretase inhibition - Google Patents

Compositions and methods for beta secretase inhibition Download PDF

Info

Publication number
ES3005508T3
ES3005508T3 ES18816475T ES18816475T ES3005508T3 ES 3005508 T3 ES3005508 T3 ES 3005508T3 ES 18816475 T ES18816475 T ES 18816475T ES 18816475 T ES18816475 T ES 18816475T ES 3005508 T3 ES3005508 T3 ES 3005508T3
Authority
ES
Spain
Prior art keywords
less
baicalein
chrysin
oroxylin
secretase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18816475T
Other languages
English (en)
Spanish (es)
Inventor
Muhammed Majeed
Kalyanam Nagabhushanam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sami Chemicals and Extracts Ltd
Original Assignee
Sami Chemicals and Extracts Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sami Chemicals and Extracts Ltd filed Critical Sami Chemicals and Extracts Ltd
Application granted granted Critical
Publication of ES3005508T3 publication Critical patent/ES3005508T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Confectionery (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES18816475T 2017-06-15 2018-06-14 Compositions and methods for beta secretase inhibition Active ES3005508T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762520141P 2017-06-15 2017-06-15
PCT/US2018/037454 WO2018232063A1 (en) 2017-06-15 2018-06-14 Compositions and methods for beta secretase inhibition

Publications (1)

Publication Number Publication Date
ES3005508T3 true ES3005508T3 (en) 2025-03-14

Family

ID=64655980

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18816475T Active ES3005508T3 (en) 2017-06-15 2018-06-14 Compositions and methods for beta secretase inhibition

Country Status (9)

Country Link
US (2) US11458117B2 (enExample)
EP (2) EP3638277B1 (enExample)
JP (2) JP7209645B2 (enExample)
KR (2) KR20190134809A (enExample)
CA (2) CA3063751C (enExample)
ES (1) ES3005508T3 (enExample)
FI (1) FI3638277T3 (enExample)
PL (2) PL3638277T3 (enExample)
WO (2) WO2018232063A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018232063A1 (en) * 2017-06-15 2018-12-20 Muhammed Majeed Compositions and methods for beta secretase inhibition
US12465585B2 (en) * 2018-06-15 2025-11-11 Sami-Sabinsa Group Limited Compositions for the management of seizure induced neurotoxicity
CN110115712A (zh) * 2019-07-04 2019-08-13 兰州大学 一种同时激活氧化磷酸化通路和抑制糖酵解途径的激活剂及其应用
KR20220049575A (ko) * 2019-08-26 2022-04-21 새미-사빈사 그룹 리미티드 식물 활성물질 및 이의 오염 방지 효과
CN114246879B (zh) * 2021-12-30 2023-10-27 沈阳兴齐眼药股份有限公司 木蝴蝶苷b在制备用于预防、控制和/或治疗眼部疾病药物中的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034387B2 (en) * 2002-04-30 2011-10-11 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
WO2003092599A2 (en) * 2002-04-30 2003-11-13 Unigen Pharmaceuticals, Inc. Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
US8945518B2 (en) * 2002-04-30 2015-02-03 Unigen, Inc. Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions
WO2005020932A2 (en) * 2003-09-02 2005-03-10 Unigen Pharmaceuticals, Inc. Formulation of a mixture of free-b-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
JP2009527461A (ja) * 2006-01-09 2009-07-30 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ 胃腸毒性、関連する症状及び潰瘍の処置のための天然作用物質
WO2007096739A2 (en) * 2006-02-21 2007-08-30 Council Of Scientific And Industrial Research Intestinal alpha-glucosidase inhibitors and a process for the isolation and use thereof
EP2007385A4 (en) 2006-03-23 2010-08-18 Sinai School Medicine CARDIOVASCULAR COMPOSITION AND ITS USE FOR THE TREATMENT OF MORBUS ALZHEIMER
KR20080008929A (ko) * 2006-11-20 2008-01-24 대한민국(관리부서 식품의약품 안전청장) 오록실린 ａ를 함유하는 인지 기능 장애 관련 질환의 예방및 개선용 건강기능식품
BR112015004418A2 (pt) * 2012-08-29 2017-07-04 Mannkind Corp composição de pó seco inalável, sistema de liberação de fármaco, processo para formar uma partícula e kit.
WO2018089325A1 (en) * 2016-11-11 2018-05-17 Muhammed Majeed Composition containing oroxylin a and method of extraction thereof
WO2018232063A1 (en) 2017-06-15 2018-12-20 Muhammed Majeed Compositions and methods for beta secretase inhibition

Also Published As

Publication number Publication date
PL3638278T3 (pl) 2022-10-03
JP7209645B2 (ja) 2023-01-20
US20180360800A1 (en) 2018-12-20
CA3063757A1 (en) 2018-12-20
CA3063751C (en) 2023-01-03
US20180360801A1 (en) 2018-12-20
US11458117B2 (en) 2022-10-04
PL3638277T3 (pl) 2025-03-10
JP2020523372A (ja) 2020-08-06
EP3638277A4 (en) 2021-03-17
EP3638277B1 (en) 2024-10-09
CA3063751A1 (en) 2018-12-20
KR20190134809A (ko) 2019-12-04
EP3638278A4 (en) 2021-03-17
EP3638277A1 (en) 2020-04-22
EP3638278A1 (en) 2020-04-22
JP6796217B2 (ja) 2020-12-02
WO2018232224A1 (en) 2018-12-20
KR20190131589A (ko) 2019-11-26
CA3063757C (en) 2023-08-01
WO2018232063A1 (en) 2018-12-20
JP2020523342A (ja) 2020-08-06
EP3638278B1 (en) 2022-05-11
US10894029B2 (en) 2021-01-19
FI3638277T3 (fi) 2025-01-10

Similar Documents

Publication Publication Date Title
ES3005508T3 (en) Compositions and methods for beta secretase inhibition
Fujikake et al. Association between autophagy and neurodegenerative diseases
Majd et al. Alzheimer’s disease and cancer: when two monsters cannot be together
MacLeod et al. The role and therapeutic targeting of α-, β-and γ-secretase in Alzheimer's disease
Ly et al. Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes
Niranjan Molecular basis of etiological implications in Alzheimer’s disease: focus on neuroinflammation
Xuan et al. Valproic acid alleviates memory deficits and attenuates amyloid-β deposition in transgenic mouse model of Alzheimer’s disease
Bai et al. Attenuation of Pb-induced Aβ generation and autophagic dysfunction via activation of SIRT1: Neuroprotective properties of resveratrol
Bhounsule et al. Cyclin dependent kinase 5: A novel avenue for Alzheimer’s disease
Zhang et al. Pseudoginsenoside-F11 alleviates cognitive deficits and Alzheimer’s disease-type pathologies in SAMP8 mice
Motyl et al. Alpha-synuclein alters differently gene expression of Sirts, PARPs and other stress response proteins: implications for neurodegenerative disorders
Kowalska et al. Genetic variants and oxidative stress in Alzheimer’s disease
Gatti et al. Oxidative stress in Alzheimer’s disease: in vitro therapeutic effect of amniotic fluid stem cells extracellular vesicles
Yoon et al. Rosiglitazone reduces tau phosphorylation via JNK inhibition in the hippocampus of rats with type 2 diabetes and tau transfected SH-SY5Y cells
Lasure et al. Quercetin ameliorates neuroinflammatory and neurodegenerative biomarkers in the brain and improves neurobehavioral parameters in a repeated intranasal amyloid-beta exposed model of Alzheimer's disease
WO2016024010A1 (en) Perk activator for the treatment of neurodegenerative diseases
Grimm et al. The impact of capsaicinoids on APP processing in Alzheimer’s disease in SH-SY5Y cells
Khairallah et al. Alzheimer’s disease: current status of etiopathogenesis and therapeutic strategies
Pasinetti et al. Development of a grape seed polyphenolic extract with anti‐oligomeric activity as a novel treatment in progressive supranuclear palsy and other tauopathies
Sun et al. AdipoRon promotes amyloid‐β clearance through enhancing autophagy via nuclear GAPDH‐induced sirtuin 1 activation in Alzheimer's disease
Van Leeuwen et al. Frameshift proteins in Alzheimer's disease and in other conformational disorders: time for the ubiquitin-proteasome system
Biberoglu et al. Azure B affects amyloid precursor protein metabolism in PS70 cells
US20250339422A1 (en) Methods for enhancing cellular clearance of pathological molecules via activation of the cellular protein ykt6
Zidan et al. Memantine/Rosuvastatin Therapy Abrogates Cognitive and Hippocampal Injury in an Experimental Model of Alzheimer's Disease in Rats: Role of TGF-β1/Smad Signaling Pathway and Amyloid-β Clearance
Chen et al. Inhibitor kappa B kinase β, modulated by DJ-1/p-VHL, reduces phosphorylated tau (p-tau) accumulation via autophagy in Alzheimer’s disease model